期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤坏死因子α拮抗药治疗类风湿关节炎安全性评价 被引量：2

下载PDF
导出
摘要 类风湿关节炎（rheumatoid arthritis，RA）是一种女性多发、侵犯外周关节及其周围组织、以骨关节持续、反复的滑膜细胞增生、破坏为特点的自身免疫性疾病，临床常无特异的系统性表现，多数患者数年后可发生关节变形和功能受损，并可缩短预期寿命。因此，本病治疗目标是以最小的药物副反应减轻症状，减少致死与致残。肿瘤坏死因子α（TNFα）是在感染或炎性刺激时产生的促炎因子，近年来，发现其虽有免疫保护作用，
作者 沈思钰 戴弌 张玉臣 张俊慧 张永文 董晓蕾 赵凌杰 蔡辉
机构地区 南京军区南京总医院风湿免疫专科 同济大学附属同济医院药剂科 南京大学医学院临床学院
出处 《药物流行病学杂志》 CAS 2008年第5期295-297,共3页 Chinese Journal of Pharmacoepidemiology
关键词 肿瘤坏死因子α拮抗药 英夫利昔单抗 依那西普 阿达木单抗 类凤湿关节炎 淋巴瘤 EB病毒
分类号 R593.22 [医药卫生—内科学]
  • 相关文献

参考文献16

  • 1Callen JP. Complications and adverse reactions in the use of newer biologic agents [ J ]. Semin Cutan Med Surg, 2007,26 ( 1 ) :6-14
  • 2Desai SB, Furst DE. Problems encountered during antitumour necrosis factor therapy [ J ]. Best Pract Res Clin Rheumatol,2006,20( 4 ) :757-790
  • 3吴廷珫,傅鹰.类风湿关节炎的药物治疗——循证性诊疗指南综述[J].药物流行病学杂志,2004,13(3):159-162. 被引量：6
  • 4Hoshida Y, Tomita Y, Zhiming D, et al. Lymphoproliferatire disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection [ J]. Int J Cancer,2004,108 ( 3 ) :443-449
  • 5Hoshida Y, Xu JX; Fujita S,et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication[J]. J Rheumatol ,2007 ,34 ( 2 ) :322-331
  • 6Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients [ J ]. Arthritis Rheum, 2004,50 ( 6 ) : 1740-1751
  • 7Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration [ J ]. Arthritis Rheum,2002,46 ( 12 ) : 3151-3158
  • 8Quartuccio L, De Re V, Fabris M, et al. Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecuiar characterization [ J ]. Haematologica, 2006, 91 (5) :691-694
  • 9Geborek P, Bladstrom A, Turesson C, et al. Turnout necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas [ J ]. Ann Rheum Dis, 2005, 64(5) :699-703
  • 10Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease [ J ]. J Pediatr Gastroenterol Nutr,2007,44 ( 2 ) : 265-267

二级参考文献6

  • 1Scott DL, Shipley M, Dawson A, et al.The clinical management of rheumatoid arthritis and osteoarthtitis: Strategies for improving clinical effectiveness[EB/OL].www.msecportal .org/portal/editorial/publicpages/bsr /536883013/6.doc, /2003-12
  • 2ACR.Guidelines for the management of rheumatoid arthritis 2002 update.Arthritis Rheumatism, 2002, 46 (2):328-346 (www.rheumatology.org/publications/guidelines/raguidelines02.pd f)
  • 3GUIPCAR.Clinical practice guideline for the management of rheumatoid arthritis [ EB/OL].www.guideline.gov/guidelines/ftngc- 2909 -guipcar.pdf, 2001/2003-12
  • 4SIGN.Management of early rheumaloid arthritis.www.sign.ac.uk /pdf /qrg48.pdf .2001/2003-12
  • 5陈波,傅鹰.循证性临床指南主要英文网站的搜集和简介[J].药物流行病学杂志,2002,11(2):90-93. 被引量：11
  • 6类风湿关节炎诊治指南(草案)[J].中华风湿病学杂志,2003,7(4):250-254. 被引量：430

共引文献5

同被引文献17

  • 1SCHEINFELD N. Adalimumab HUMIRA a review[J]. J Drugs Dermatol, 2003, 2 (4) :375 - 377.
  • 2SHIMIZU Y, TAKEDA T, MATSUMOTO R, et al. Clinical efficacy of adalimumab for a postoperative marginal ulcer in gastroin- testinal Behqet disease [ J ]. Nihon Shokakibyo Gakkai Zasshi, 2012, 109(5) :774 -780.
  • 3BOLDUC C, BISSONNETTE R. Safety and efficacy of adalimumab for the treatment of severe alopecia areata: case series of three patients[J]. J Cutan Med Surg, 2012, 16(4) :257 -260.
  • 4SIEPER J, VAN DER HEIJDE D, DOUGADOS M, et al. Efficacy and safety of adallmumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1) [J]. Ann Rheum Dis, 2012, [ Epub ahead of print ].
  • 5TUBACH F, SALMON D, RAVAUD P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy [ J ]. Arthritis Rheum, 2009, 60 (7) : 1884 - 1893.
  • 6DIXON WG, HYRICH KL, WATSON KD, et al. Drug-speclfic risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British society for rheu- matology biologics register (BSRBR) [ J ]. Ann Rheum Dis, 2010, 69(3) : 522 -528.
  • 7VOJACKOVA N, FIALOVA J, VANOUSOVA. D, et al. Pemphigus vulgaris treated with adalimumab: case study[ J]. Dermatol Ther, 2012, 25(1) :95 -97.
  • 8TICHY M, ZAPLETALOVA J. Experience with the systemic treatment of severe forms of psoriasis [ J ]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2012, 156( 1 ) :29 -40.
  • 9安富荣,崔岚,王勤.阿达木单抗治疗自身免疫疾病的临床研究进展[J].中国新药与临床杂志,2010,29(6):410-415. 被引量：18
  • 10张玲玲,刘云洁,童彤,吴颖其,赵文娣,李培培,魏伟.DBA/1小鼠胶原性关节炎模型建立方法及评价指标[J].中国药理学通报,2010,26(8):1108-1111. 被引量：31

引证文献2

二级引证文献4

药物流行病学杂志
2008年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部